Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Neoadjuvant chemotherapy in sarcoma].

Jean-Yves Blay1, Sylvie Bonvalot, Jérôme Fayette

  • 1Hôpital Edouard-Herriot et Unité Inserm U590, Centre Léon-Bérard, 28, rue Laennec, 69008 Lyon. blay@lyon.fnclcc.fr

Bulletin Du Cancer
|December 6, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

MiT fusions, TSC1-TSC2 divergence, and stem-like programs reveal distinct origins and vulnerabilities in PEComa.

Nature communications·2026
Same author

A pooled analysis of phase 2 clinical trials in advanced chordoma.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Overall survival of patients with localized soft tissue sarcoma treated with or without adjuvant chemotherapy (DEEPSARC): a real world nationwide retrospective cohort study in France.

EClinicalMedicine·2026
Same author

Deep Learning Predicts Mutations and Outcomes in Gastrointestinal Stromal Tumors from Whole-Slide Images.

Cancer research·2026
Same author

Metastatic Ewing Sarcoma, Patterns of Care and Outcomes of Patients in a Real-Life National Setting Over a Decade.

Cancer medicine·2026
Same author

Characteristics and outcome of intra-abdominal desmoid-type fibromatosis.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2026

Neoadjuvant chemotherapy for soft tissue sarcomas is experimental. It may help achieve surgical tumor removal in advanced cases but offers no survival benefit when complete resection is possible.

Area of Science:

  • Oncology
  • Surgical Oncology
  • Medical Oncology

Context:

  • Neoadjuvant chemotherapy is an experimental approach for soft tissue sarcomas.
  • Guidelines are proposed by the French Sarcoma Group for its clinical use.
  • Its role is primarily in locally advanced tumors where complete surgical removal is challenging or leads to mutilation.

Purpose:

  • To define clinical practice guidelines for neoadjuvant chemotherapy in soft tissue sarcomas.
  • To outline specific situations where neoadjuvant chemotherapy may be considered.
  • To guide the selection of chemotherapy regimens based on patient factors.

Summary:

  • Neoadjuvant chemotherapy is recommended for locally advanced soft tissue sarcomas to facilitate R0/R1 resection or conservative surgery.

Related Experiment Videos

  • It is not indicated when complete tumor removal (R0/R1) is achievable without neoadjuvant treatment.
  • Combined doxorubicin and ifosfamide is suggested for younger patients, while single-agent doxorubicin is preferred for elderly or frail patients.

    • Impact:

    • Provides a framework for multidisciplinary decision-making in sarcoma treatment.
    • Aims to optimize neoadjuvant chemotherapy use, reserving it for cases with potential functional or oncologic benefit.
    • Highlights the need for individualized treatment strategies in soft tissue sarcoma management.